Everolimus Related Pneumonitis in MBC

N/ACompletedNCT03730428

Fudan University86 enrolled

Overview

To study the drug-related pneumonitis during mTOR inhibitor therapy in patients with metastatic breast cancer.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Everolimus Pneumonitis

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Postmenopausal woman (or premenopausal women treated with LHRHa) diagnosed with HR+，HER2- metastatic breast cancer 2. Treated with everolimus for at least one month in metastatic setting 3. With baseline and at least one follow-up chest CT during everolimus therapy. 4. Complete medical history Exclusion Criteria: 1. Incomplete medical history 2. Radiographic imaging unavailable

Locations (1)

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, China

Outcomes

Primary Outcomes

radiographic pattern

Quantitive measure of lung CT

Time frame: 2 months

PFS

Progression free survival

Time frame: 2 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.